BanuAbbas(Karimi)Karimi-ShahMD
Pulmonology • Falls Church, VACritical Care Medicine, Pleural Disease
Physician
Are you Dr. Karimi-Shah?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 78 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3300 Gallows Road Department of Medicine
Falls Church, VA 22042Phone+1 703-776-3582
Summary
- Dr. Banu (Karimi) Karimi-Shah, MD is a pulmonologist in Falls Church, Virginia. She is currently licensed to practice medicine in Virginia, Maryland, and Massachusetts. She is affiliated with Inova Loudoun Hospital.
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2006- Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Boston University School of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2009 - 2026
MD State Medical License 2008 - 2010
MA State Medical License 2002 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 18 citationsMeaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Sympo...Ganesh Raghu, Marya Ghazipura, Thomas R Fleming, Kerri I Aronson, Jürgen Behr
American Journal of Respiratory and Critical Care Medicine. 2024-03-15 - 11 citationsA Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury.David R Cassatt, Alex Gorovets, Banu Karimi-Shah, Rosemary Roberts, Paul W Price
Radiation Research. 2022-04-01 - 1 citationsA Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury.Merriline M Satyamitra, David R Cassatt, Libero Marzella
Radiation Research. 2022-04-01
Press Mentions
FDA Advisors Tepid on Drug Candidate for COVID InpatientsNovember 10th, 2022
FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR MutationsJune 25th, 2019
FDA Expands Approval of CF Treatment to Include Patients Ages 6 and OlderJune 24th, 2019- Join now to see all
